Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as a sterile solution for intravenous use. It treats hemophilia B (Factor IX deficiency) in patients who require replacement therapy.

GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Immunine is a coagulation factor used to manage disorders of the intrinsic clotting pathway, primarily hemophilia B. - Hemophilia B: provides replacement of deficient factor IX to achieve hemostasis. - Surgical prophylaxis in hemophilia B: maintains adequate factor IX levels during operative procedures. - Routine prophylaxis in severe hemophilia B: reduces frequency of spontaneous bleeding episodes.

Immunine may be associated with infusion‑related reactions and other adverse events.

Common Side Effects: - Infusion site erythema or swelling. - Mild fever or chills. - Headache. - Nausea. - Arthralgia. - Transient increase in liver enzymes.

Serious or Rare Side Effects: - Development of inhibitory antibodies (inhibitors) against factor IX. - Anaphylactic or severe allergic reactions. - Thromboembolic events. - Transmission of viral pathogens (rare with recombinant products). - Hemolysis. - Severe hypertension.

Before initiating therapy, consider the following precautions. - Monitor inhibitor development: test for anti‑factor IX antibodies periodically. - Assess thrombosis risk: avoid in patients with a history of thromboembolic disease. - Avoid concurrent use of other clotting factor products unless directed. - Use aseptic technique during preparation and administration. - Pregnancy and breastfeeding: safety unknown; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine can interact with other medications that affect coagulation.

Major Interactions (Avoid): - Concomitant procoagulant agents (e.g., activated prothrombin complex concentrates) may increase thrombosis risk. - Concurrent anticoagulants (e.g., warfarin, direct oral anticoagulants) may reduce the efficacy of factor IX replacement. - Use with immunogenic biologics may heighten inhibitor formation.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics may alter plasma factor IX levels. - Live vaccines may have an altered immune response. - Co‑administration of other plasma‑derived products may require monitoring for additive clotting effects.